Epigenetic Moderators of Naltrexone Efficacy for Alcohol Use Disorder

Request Access

Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status

Joseph P. Schacht, P. Randall, P. Latham, et al. (2017). Neuropsychopharmacology. Cited 78 times. https://doi.org/10.1038/npp.2017.74

Nicotine‐Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence

R. Anton, P. Latham, K. Voronin, et al. (2018). Alcoholism: Clinical and Experimental Research. Cited 23 times. https://doi.org/10.1111/acer.13601

Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.

R. Anton, K. Voronin, S. Book, et al. (2020). Alcoholism, clinical and experimental research. Cited 10 times. https://doi.org/10.1111/acer.14431

Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: A randomized trial

Joseph P. Schacht, Michaela Hoffman, Brian H. Chen, et al. (2021). The pharmacogenomics journal. Cited 6 times. https://doi.org/10.1038/s41397-021-00250-8